Core Scientific, Inc.
CORZ · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.01 | -0.00 | 0.07 |
| FCF Yield | -2.15% | -1.61% | -5.65% | -0.35% |
| EV / EBITDA | -49.59 | -9,478.11 | -137.65 | -19.86 |
| Quality | ||||
| ROIC | -4.02% | -1.84% | -2.92% | -2.67% |
| Gross Margin | 4.66% | 6.39% | 10.33% | 5.02% |
| Cash Conversion Ratio | -0.90 | -0.04 | -0.07 | -0.07 |
| Growth | ||||
| Revenue 3-Year CAGR | -11.48% | -13.12% | -10.25% | -7.26% |
| Free Cash Flow Growth | -40.74% | 32.35% | -762.84% | 40.98% |
| Safety | ||||
| Net Debt / EBITDA | -4.75 | -916.59 | -24.59 | -1.55 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -35.02 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -246.95 | 23.93 | -6.83 | -18.26 |